e) extracting the composition with a mixture of immiscible solvents (e.g., dichloromethane/methanol) to form an organic phase; and f) adding a suitable solvent to the organic phase, to thereby form said crystalline free base form of the compound. A further purpose is a method of treating hepatocellular carcinoma in a subject in need thereof comprising administering to said subject a treatment effective amount of a crystalline form compound as described herein. In some embodiments, hepatocellular carcinoma has altered FGFR4 and/or FGF19 status (*e.g.*, increased expression of FGFR4 and/or FGF19). A further purpose is a method of treating hepatocellular carcinoma in a subject in need thereof, comprising: detecting an altered FGFR4 and/or FGF19 status (*e.g.*, increased expression of FGFR4 and/or FGF19) in a biological sample containing cells of said hepatocellular carcinoma, and if said hepatocellular carcinoma has said altered FGFR4 and/or FGF19 status, administering a crystalline form compound as described herein to said subject in a treatment-effective amount. A further purpose is the use of a crystalline form compound as described herein in a method of treatment of hepatocellular carcinoma. A further purpose is the use of a crystalline form compound as described herein in the preparation of a medicament for the treatment of hepatocellular carcinoma. In one aspect, the present invention is directed to the use of a crystalline form of the compound of the present invention or the pharmaceutical composition of the present invention in the manufacture of a medicament for treating hepatocellular carcinoma in a subject in need thereof, wherein the use comprises: detecting an altered FGFR4 and/or FGF19 status in a biological sample containing cells of said hepatocellular carcinoma, and if said hepatocellular carcinoma has said altered FGFR4 and/or FGF19 status said medicament is to be administered to said subject in a treatment-effective amount.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 presents the results of *in vivo* efficacy testing in hepatocellular carcinoma model using HUH7 cells. Compound 108 (25 mg/kg or 37.5 mg/kg) or Vehicle control was administered via intraperitoneal injection, and tumor volume was measured twice weekly over the course of 15 days.

FIG. 2 presents the results of *in vivo* efficacy testing in hepatocellular carcinoma model using HEP3B cells. Compound 108 (12.5 mg/kg, 25 mg/kg or 37.5 mg/kg) or Vehicle control was administered via intraperitoneal injection, and tumor volume was measured twice weekly over the course of 15 days.

FIG. 3 presents the results of *in vivo* efficacy testing in hepatocellular carcinoma model using JHH7 cells. Compound 108 (12.5 mg/kg, 25 mg/kg or 37.5 mg/kg) or Vehicle control was administered via intraperitoneal injection, and tumor volume was measured twice weekly over the course of 15 days.

FIG. 4 presents the results of comparative *in vivo* efficacy testing in hepatocellular

f) adding a suitable solvent to the organic phase,

to thereby form said crystalline free base form compound of claim 2.

21. The process of claim 20, wherein said acid of step b) is trifluoroacetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid or methanesulfonic acid.

22. The process of claim 20 or claim 21, wherein the suitable solvent of step f) is dichloromethane, acetonitrile, 1,2-dichloroethane, or aqueous dimethyl formamide.

23. Use of the compound of any one of claims 1-17 or the pharmaceutical composition of claim 18 or claim 19 in the manufacture of a medicament for treating hepatocellular carcinoma in a subject in need thereof.

24. The use of claim 23, wherein said hepatocellular carcinoma has altered FGFR4 and/or FGF19 status.

25. The use of claim 24, wherein said altered FGFR4 and/or FGF19 status comprises increased expression of FGFR4 and/or FGF19.

26. Use of a crystalline form of the compound of any one of claims 1-17 or the pharmaceutical composition of claim 18 or claim 19 in the manufacture of a medicament for treating hepatocellular carcinoma in a subject in need thereof, wherein the use comprises:

detecting an altered FGFR4 and/or FGF19 status in a biological sample containing cells of said hepatocellular carcinoma, and if said hepatocellular carcinoma has said altered FGFR4 and/or FGF19 status said medicament is to be administered to said subject in a treatment-effective amount.

27. The use of claim 26, wherein said altered FGFR4 and/or FGF19 status comprises increased expression of FGFR4 and/or FGF19.